Soleno Therapeutics (NASDAQ: SLNO) shares plummeted 26.69% in pre-market trading on Wednesday, continuing a downward trend that began in after-hours trading on Tuesday. This significant drop comes as a surprise to many investors, given the company's strong third-quarter 2025 financial results released late Tuesday.

The biotech firm, focused on developing treatments for rare diseases, reported impressive numbers for the quarter ended September 30, 2025: - Revenue of $66.0 million, surpassing analyst expectations of $48.1 million - Net income of $26.0 million, or $0.47 per diluted share, significantly beating the mean analyst forecast of $0.05 - Operating income of $22.1 million These results mark a substantial improvement from the same period last year when the company reported a loss of $1.83 per share and no revenue.

Despite these positive financials and the successful U.S. launch of VYKAT XR, Soleno's treatment for hyperphagia in patients with Prader-Willi syndrome (PWS), investors seem to be reacting negatively. The company reported 1,043 patient start forms received since the drug's approval in March 2025, with 764 active patients on the drug as of September 30. However, this apparent success has not translated into stock price gains. Possible explanations for the sell-off include: 1. Valuation concerns: The stock may have been priced for perfection, and even strong results couldn't justify its current valuation. 2. Future growth worries: Investors might be questioning the long-term growth potential of VYKAT XR or the company's pipeline. 3. Competitive landscape: There could be concerns about potential competition in the PWS treatment market. 4. Profit-taking: Some investors may be selling to lock in gains, as biotech stocks can be volatile following earnings releases. As the market continues to digest the full earnings report and management's commentary, it remains to be seen whether this pre-market plunge will persist or if the stock will recover based on its strong fundamentals.